Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system.

The study identified potential Palbociclib-related AEs and offered warnings for special AEs, providing further data for palbociclib safety studies in breast cancer patients. Nonetheless, prospective clinical trials are needed to validate these results and explain their relationship.